Form 4: Cytosorbents Corp Executive Granted Stock Options Tied to Regulatory Approvals

Vincent Capponi, President and COO of Cytosorbents Corp, received stock options that vest upon regulatory clearance of DrugSorb-ATR in the U.S. and Canada.

Summary

• Vincent Capponi, President and COO of Cytosorbents Corp, was granted stock options on October 4, 2024.
• 100,000 stock options will vest upon FDA clearance or approval of DrugSorb-ATR before June 30, 2026, contingent on continued service.
• 50,000 stock options will vest upon Health Canada clearance or approval of DrugSorb-ATR before June 30, 2026, contingent on continued service.
• The exercise price for both sets of options is $1.19.
• The options expire on October 4, 2034.
• The stock options were granted pursuant to the Amended and Restated CytoSorbents Corporation 2014 Long-Term Incentive Plan.

Sentiment

Score: 7

Explanation: The document itself is neutral, simply reporting the grant of stock options. The positive sentiment stems from the alignment of executive incentives with regulatory success, which is generally viewed favorably.

Positives

• The granting of stock options to a key executive aligns their interests with the company's success in achieving regulatory milestones.
• The vesting of options is tied to specific, measurable goals (FDA and Health Canada approvals), which can incentivize performance.
• The long-term expiration date (October 4, 2034) encourages a long-term focus from the executive.

Risks

• Failure to obtain FDA or Health Canada clearance for DrugSorb-ATR before June 30, 2026, will result in the options not vesting.
• The executive's departure before the vesting date would also result in the forfeiture of the options.

Future Outlook

The vesting of the stock options is contingent on future regulatory approvals for DrugSorb-ATR.

Industry Context

Stock options are a common form of executive compensation in the biotechnology industry, often tied to achieving key milestones such as regulatory approvals.

Comparison to Industry Standards

• Many biotech companies use stock options to incentivize executives, with vesting often tied to clinical trial results, regulatory submissions, and approvals.
• The specific terms of the options, such as the exercise price, vesting schedule, and expiration date, are generally comparable to industry standards for companies of similar size and stage of development.
• Companies like BioCryst Pharmaceuticals and Sarepta Therapeutics also use stock options tied to regulatory and clinical milestones.

Stakeholder Impact

• Shareholders may view the stock options positively as they incentivize management to achieve regulatory milestones.
• Employees may be motivated by the potential for the company's success and the achievement of regulatory approvals.
• The successful approval of DrugSorb-ATR could benefit patients and healthcare providers.

Next Steps

• The company will need to achieve FDA and Health Canada clearance or approval for DrugSorb-ATR by June 30, 2026, for the options to vest.
• The executive must remain employed by the company through the vesting dates.

Key Dates